Links to media articles about Rigvir

2018

August

1) The court case, in which Rigvir manufacturers SIA Latima had sued Latvian cardiologist Dr. Andris Skride for criticising Rigvir, its lack of evidence, and saying it is an unproven medication that has turned into a business project, has concluded. Instead of providing evidence contrary to the claims of Dr. Skride, the manufacturers of Rigvir have annulled their lawsuit against him. Latvian / Automated translation in English

2) SIA Latima, the manufacturer of Rigvir, publishes a public procurement announcement for a toxicology study in rats.  Latvian / Automated translation in English

June

Italian Association for Cancer Research (AIRC) publishes a warning article about virotherapy and unproven Rigvir in the “Disinformation” section of its official website. Link to AIRC article, Italian version

May

Health Inspectorate of Slovenia is investigating a physician Kalan Živčec who has prescribed Rigvir to her  patients. Original in Slovenian / Automated translation. Other source in Slovenian available here (paywall).

2017

December

Manufacturer of Rigvir loses in an administrative court case against Health Inspectorate of Latvia and Inspectorate’s initial decision in 2016 regardingthe applied fine for illegal advertising of Rigvir is not cancelled: Original in Latvian/Microsoft Bing automated translation

October
  • A major investigative magazine IR reports – State Drug Agency of Latvia hid a completely negative expert conclusion about the efficacy evidence for Rigvir, which would have prevented the renewal of its license and casts doubt on the initial registration (only Google Translate version for now)
  •  A representative of Rigvir clarifies his position of scientific evidence: “We do not need scientific evidence to see its effectiveness”. Despite lack of evidence, Ministry of Health defends Rigvir, asking oncologists to prove that it is not effective and calling professional associations “social groups”. Minister of Health Anda Čakša is quoted saying: “A letter by some social group saying they don’t like something – it’s just not helpful. Show us data that this medicine does not work for your patients. We don’t have anything to react to at the moment.
  • Mike Collier, Public broadcasting of Latvia, suggests a possible solution to Rigvir dilemma: How to resolve Rigvir
September
  • Critical analysis of Rigvir by a prominent science-based medicine advocate and surgical oncologist Dr. David Gorski

Part 1: Rigvir is most likely cancer quackery
Part 2: Unethical marketing via quack film Truth About Cancer, deconstruction of testimonials
Part 3: Rigvir strikes back, or: A conversation with a Rigvir flack 
Part 4: Analysis of a dubious case report

February to August
  • Media reports repetitive attempts to intimidate the medical professionals who requested data on evidence of Rigvir efficacy: Latvian article / automated translation.
  • Dr. Andris Skride, one of the signatories of the letter to the Health Ministry is sued  by Rigvir representatives. Another signatory, Dr. Santa Purviņa, the Head of Pharmacology Department in Riga Stradins University, is receiving letters from Rigvir lawyers directed to her university: Latvian article / automated translation. 
  • July
  • SIA Latima, manufacturer of Rigvir, fails to receive further European Commission funding under Horizon2020 project, progress stops at Phase 1 and initial 50 000 EUR for feasibility studies. Manufacturer’s PR spin follows as  “seal of approval“.
  • February
    • Three leading Latvian medical associations – oncologists, oncologists-chemotherapists and rare disease specialists, as well as the head of pharmacology department in Rīgas Stradiņa University request to remove Rigvir from Latvian drug register due to insufficient evidence of efficacy, to review clinical guidelines and to evaluate conflicts of interest: for now only Google Translate EN version
    • Ministry of Health responds in February 2017: Rigvir registration and compensation status to be reviewed. No further public updates are given by the ministry until October 2017.

2016

October
September
August

Latvian Inspectorate of Health publishes a decision to apply a fine to SIA Latima, the manufacturer of Rigvir. Inspection concludes that Rigvir advertisements constitute unfair commercial practice, they violate advertising laws of prescription medicine to the general public, and the content of advertisements does not match the registered product specification.

SIA Latima claims that they will appeal the fine.

July

A local skeptic and a cancer survivor (TW handle: @zimbabve) submits a complaint to the Health Inspectorate of Latvia regarding Rigvir and makes it publicly available, and Latvian media picks up the story (automated translation). Complaint contains examples of illegal, misleading and prolonged advertising of Rigvir directly to general public and cancer patients in magazines, newspapers, in a cancer patient support group, as well as advertising it off-label for multiple forms of cancer. Representatives of Rigvir claim that the official complaint is a part of a “black PR” campaign – a common excuse in Latvian political and business environment.

Other links to earlier articles, mentioning Rigvir or its collaboration partners in Mexico